Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Pavlidis, N ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cancer of unknown primary; Clinicopathological subsets; Treatment

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE PLUS OXALIPLATIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN; PACLITAXEL; PLATINUM COMPLEX; PROSTATE SPECIFIC ANTIGEN; VINDESINE;

ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER LOCALIZATION; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CERVICAL LYMPH NODE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COLON ADENOCARCINOMA; DISEASE ASSOCIATION; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; LIVER CANCER; METASTASIS; NEUROENDOCRINE TUMOR; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

ADENOCARCINOMA; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; NEOPLASMS, UNKNOWN PRIMARY; PLATINUM; PROGNOSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 84866770439     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds317     Document Type: Article

References (30)

1. Pavlidis N, Briasoulis E, Hainsworth J et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003; 39: 1990-2005.
2. Pavlidis N, Fizazi K. Cancer of unknown primary. Crit Rev Oncol Hematol 2009; 69(7): 271-280.
3. Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 2007; 43(14): 2026-2036.
4. Lazaridis G, Pentheroudakis G, Fountzilas G et al. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev 2008; 34: 693-700.
5. Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol 2007; 46: 592-601.
6. Golfinopoulos V, Pentheroudakis G, Salanti G et al. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multipletreatments meta-analysis. Cancer Treat Rev 2009; 35: 570-573.
7. Fizazi K, Greco FA, Pavlidis N et al. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22(Suppl. 6): vi64-vi68.
8. Hainsworth JD, Burris HA, III, Calvert SW et al. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest 2001; 19: 335-339.
9. Culine S, Ychou M, Fabbro M et al. 5-Fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site. Anticancer Res 2001; 21: 1455-1457.
10. Pouessel D, Culine S, Becht C et al. Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res 2003; 23(3C): 2801-2804.
11. Hainsworth JD, Spigel DR, Raefsky EL et al. Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial. Cancer 2005; 104: 1992-1997.
12. Hainsworth JD, Spigel DR, Burris HA, III et al. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 2010; 116(10): 2448-2454.
13. Hainsworth JD, Spigel DR, Thompson DS et al. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist 2009; 14(12): 1189-1197.
14. Pentheroudakis G, Pavlidis N. Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Oncol Hematol 2010; 75(1): 27-42.
15. Pentheroudakis G, Lazaridis G, Pavlidis N. Axillary nodal metastases from carcinoma of unknown primary (CUPAX): a systematic review of published evidence. Breast Cancer Res Treat 2010; 119: 1-11.
16. Pentheroudakis G, Stoyianni A, Pavlidis N. Cancer of unknown primary patients with midline nodal distribution: midway between poor and favourable prognosis. Cancer Treat Rev 2011; 37(2): 120-126.
17. Pavlidis N, Pentheroudakis G, Plataniotis G. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP. Clin Transl Oncol 2009; 11: 340-348.
18. Stoyianni A, Pentheroudakis G, Pavlidis N. Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumours. Cancer Treat Rev 2011; 37(5): 358-365.
19. Varadhachary GR, Raber MN, Matamoros A et al. Carcinoma of unknown primary with a colon-cancer profile - changing paradigm and emerging definitions. Lancet Oncol 2008; 9: 596-599.
20. Culine S. Prognostic factors in unknown primary cancer. Semin Oncol 2009; 36 (1): 60-64.
21. Seve P, Sawyer M, Hanson J et al. The influence of comorbidities, age and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Cancer 2006; 106: 2058-2066.
22. Valentine J, Rosenthal S, Arseneau J. Combination chemotherapy for adenocarcinoma of unknown primary origin. Cancer Clin Trials 1979; 2: 265-268.
23. Fiore JJ, Kelsen DP, Gralla RJ et al. Adenocarcinoma of unknown primary origin: treatment with vindesine and doxorubicin. Cancer Treat Rep 1985; 69: 591-594.
24. Goldberg RM, Smith FP, Ueno W et al. Fluorouracil, adriamycin and mitomycin in the treatment of unknown primary. J Clin Oncol 1986; 4: 395-399.
25. Becouarn Y, Brunet R, Barbe-Gaston C. Fluorouracil, doxorubicin, cisplatin and altretanine in the treatment of metastatic carcinoma of unknown primary. Eur J Cancer Clin Oncol 1989; 25: 861-868.
26. Briasoulis E, Tsavaris N, Fountzilas G et al. Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: a Hellenic Co-operative Oncology Group Phase II study. Oncology 1998; 55: 426-430.
27. Piga A, Gesuita R, Catalano V et al. Identification of clinical prognostic factors in patients with unknown primary tumors treated with a platinum-based combination. Oncology 2005; 69: 135-144.
28. Greco FA, Burris HA, III, Erland EB et al. Carcinoma of unknown primary site. Cancer 2000; 89: 2655-2660.
29. Greco FA, Burris HA, III, Litchy S et al. Gemcitabine, carboplatin and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2002; 20: 1651-1656.
30. Hainsworth JD, Spigel DR, Litchy S et al. Phase II trial of paclitaxel, carboplatin and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006; 24: 3548-3554.